Market Place
Sourcing Support
Vaxart To Host Stockholder Fireside Chat On May 8 At 4:30 P.M. ET
01 May 2026 //
GLOBENEWSWIRE
Vaxart Appoints James Breitmeyer, M.D., Ph.D., To Board
23 Apr 2026 //
GLOBENEWSWIRE
Vaxart Enters $25M Share Purchase Deal With Lincoln Park Capital
19 Apr 2026 //
FIRSTWORD PHARMA
Vaxart Updates Business And Reveals 2025 Financial Results
12 Mar 2026 //
GLOBENEWSWIRE
Vaxart To Host Upcoming Conference Calls
03 Mar 2026 //
GLOBENEWSWIRE
Vaxart Updates Business And Reports Q3 2025 Financials
13 Nov 2025 //
GLOBENEWSWIRE
Vaxart To Host Upcoming Conference Calls
07 Nov 2025 //
GLOBENEWSWIRE
Vaxart Announces Adjournment of Special Meeting of Stockholders
08 Sep 2025 //
GLOBENEWSWIRE
Vaxart Reports Q2 2025 Financial Results and Business Update
13 Aug 2025 //
GLOBENEWSWIRE
Vaxart to Host Q2 2025 Business Update and Financial Results Call
06 Aug 2025 //
GLOBENEWSWIRE
Vaxart Announces Adjournment of Annual Meeting of Stockholders
02 Jun 2025 //
GLOBENEWSWIRE
Vaxart`s Founder Provides Video Update to Stockholders
29 May 2025 //
GLOBENEWSWIRE
Vaxart Answers FAQs from Retail Investors
28 May 2025 //
GLOBENEWSWIRE
Vaxart Approves Resolutions to Narrow Reverse Split Range
16 May 2025 //
GLOBENEWSWIRE
Vaxart approved to dose 10,000 in Phase 2b Covid-19 Trial
15 May 2025 //
GLOBENEWSWIRE
Vaxart Reports First Quarter 2025 Financial Results
13 May 2025 //
GLOBENEWSWIRE
Vaxart Answers FAQs on Stock Split in Proxy Statement
12 May 2025 //
GLOBENEWSWIRE
Vaxart to Host Q1 2025 Business Update and Financial Results Conf
02 May 2025 //
GLOBENEWSWIRE
Vaxart to Present at the Citizens Life Sciences Conference
30 Apr 2025 //
GLOBENEWSWIRE
Vaxart Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
27 Mar 2025 //
GLOBENEWSWIRE
Vaxart Reports Full Year 2024 Financial Results
20 Mar 2025 //
GLOBENEWSWIRE
Vaxart to Host 2024 Business Update Call on March 20
13 Mar 2025 //
GLOBENEWSWIRE
Vaxart Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
19 Nov 2024 //
GLOBENEWSWIRE
Vaxart Business Update & Reports Q3 2024 Financial Results
13 Nov 2024 //
GLOBENEWSWIRE
Vaxart to Host Q3 2024 Financial Results & Business Update Call
07 Nov 2024 //
GLOBENEWSWIRE
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 Aug 2024 //
GLOBENEWSWIRE
Vaxart To Host Q2 2024 Business Update Call On August 8
02 Aug 2024 //
GLOBENEWSWIRE
Vaxart provides business update
17 Jun 2024 //
GLOBENEWSWIRE
Vaxart Announces $40M Underwritten Common Stock Offering
13 Jun 2024 //
GLOBENEWSWIRE
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23 May 2024 //
GLOBENEWSWIRE
Vaxart To Host Q1 2024 Business Update And Earnings Call On May 13
07 May 2024 //
GLOBENEWSWIRE
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 Mar 2024 //
GLOBENEWSWIRE
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference
07 Mar 2024 //
GLOBENEWSWIRE
Vaxart Appoints Steven Lo as President, Chief Executive Officer, and Director
06 Mar 2024 //
GLOBENEWSWIRE
Vaxart Receives $9.27 Million BARDA Project NextGen Award
19 Jan 2024 //
GLOBENEWSWIRE
Vaxart, Inc. Announces Management Change
16 Jan 2024 //
GLOBENEWSWIRE
Vaxart Announces $10.0M Registered Direct Offering with RA Capital Management
16 Jan 2024 //
GLOBENEWSWIRE
Vaxart to Host Third Quarter 2023 Business Update & Financial Results Conference
26 Oct 2023 //
GLOBENEWSWIRE
Vaxart to Participate in Fireside Chat at 2023 Cantor Healthcare Conference
21 Sep 2023 //
GLOBENEWSWIRE
Vaxart to Host Second Quarter 2023 Financial Results Conference Call on August 3
27 Jul 2023 //
GLOBENEWSWIRE
Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement
26 Jun 2023 //
GLOBENEWSWIRE
Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote
21 Jun 2023 //
GLOBENEWSWIRE
Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock
07 Jun 2023 //
GLOBENEWSWIRE
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
06 Jun 2023 //
GLOBENEWSWIRE
Vaxart Launches Investor Program, First Event Scheduled for June 15 at 11 a.m.
31 May 2023 //
GLOBENEWSWIRE
Vaxart to Host Webcast with Key Opinion Leaders to Discuss Impact for Norovirus
17 Mar 2023 //
GLOBENEWSWIRE
Vaxart Provides Business Update and Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
Vaxart Doses First Subject in the Phase 2 Trial of Bivalent Norovirus Candidate
14 Feb 2023 //
GLOBENEWSWIRE
Vaxart Names Phillip Lee as Chief Financial Officer
19 Dec 2022 //
GLOBENEWSWIRE
Vaxart Announces Collaborative Funding from Leading Foundation to Study
01 Dec 2022 //
GLOBENEWSWIRE
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022
23 Nov 2022 //
BIOSPACE
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast
22 Nov 2022 //
GLOBENEWSWIRE
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
08 Nov 2022 //
GLOBENEWSWIRE
Vaxart to Host Q3 2022 Business Update and Financial Results Conference
20 Oct 2022 //
GLOBENEWSWIRE
Syngene set for phase-2 trial of Covid oral tablet vaccine
12 Oct 2022 //
ECONOMIC TIMES
Vaxart to Present at World Vaccine Congress Europe 2022 on October 13
10 Oct 2022 //
GLOBENEWSWIRE
Vaxart to Present at the H.C. Wainwright 24th Annual GIC
07 Sep 2022 //
GLOBENEWSWIRE
Vaxart Announces Positive Top-line Ph II Clinical Study Data Safety
01 Sep 2022 //
PRESS RELEASE
Vaxart Names Ray Stapleton CTO
31 Aug 2022 //
GLOBENEWSWIRE
